We, therefore, questioned whether expressing the MET binding domain of the MetMab antibody on the surface of T cells may generate MET-targeting CAR-T cells that are able to kill MET-overexpressing HCC cells regardless of MET pathway activation, since MET-CAR-T cells would rely on T cell functions which is independent of MET activation. The gene discussed is MET; the disease is hepatocellular carcinoma.